The future of medicine is hybrid. Human discernment will continue to be essential for patient care and drug development in the coming decades. However, it will be increasingly supported by technical systems and artificial intelligence that can record, structure, and link the growing volume of medical information. A collaboration between humans and artificial intelligence applications is already leading medicine into one of the largest paradigm shifts, thanks in part to Molecular Health solutions.
“As a pioneer in realizing precision medicine, we work to ensure that available clinical and molecular knowledge becomes accessible and usable for patient care. This makes us the ideal partner for innovative physicians, researchers, and developers.”
PhD Friedrich von Bohlen und Halbach
Chief Executive Officer
Everything we do aims to improve patient care in the long term.
Our solutions’ functionality and quality give our customers significant benefits.
By continuously integrating current health issues and patient needs into product development, we develop our solutions in a targeted way.
We know it takes people with different ideas, strengths, interests, and cultural backgrounds to make our company succeed, so we focus on diversity in our workforce and in our teams.
A cancer diagnosis changes a person’s whole life – privately as well as professionally. It presents a huge challenge to everyone. This also impacts every company, since employees are the most valuable assets …
Molecular Health is a privately-held company funded by dievini Hopp Biotech holding GmbH & Co. KG, an investment holding of the founder and former CEO of SAP, Dietmar Hopp. Dievini Hopp BioTech invests in life sciences and healthcare companies, including CureVac based in Tübingen, Germany.
Investments focus on companies in precision medicine that are developing innovative therapeutic and diagnostic methods and have the potential to enable completely new forms of treatment.
The main indications are oncology, neurology, infectious diseases, cell therapy, and improved drug formulation. The geographic focus of Dievini Hopp BioTech’s investments is Germany and Europe. Companies are supported in setting up and implementing their global development and marketing.
Bohlen und Halbach, PhD
Chief Executive Officer
Stephan Brock, PhD
Chief Technology Officer
Head of Research & Development
Burkhard G. Piper
Member of the Executive Team
Head of Finance & Administration
Jochen Theis, MD PhD
Acting Chief Medical Officer
Head of Business Unit AI Pharma Solutions
Frieda Gerdes, PhD
SVP, Head of Business Unit
Clinical Decision Support
Niels Bojunga, PhD
SVP, Head of Quality Management
Josef Hermanns, PhD
SVP, Head of Project Management
SVP, Head of Human Resources
Alena Blank-Giwojna, PhD
Manager Business Development AI Pharma Solutions
Matthias Kopf, PhD
VP, Head of Product Management
SVP, Head of Sales & Business
Marc Rauschendorf, PhD
VP, Head of Medical Affairs
VP, Head of Marketing
SVP, Head of Client Services, USA
Christof Hettich, PhD
Lawyer and Partner at RITTERSHAUS Rechtsanwälte
Mathias Hothum, PhD
Owner of HMM-Consulting
Alexander Schuth, PhD
Co-founder and COO of Denali Therapeutics
© 2021 Molecular Health GmbH
© 2020 Molecular Health GmbH